-
公开(公告)号：US20140364408A1
公开(公告)日：2014-12-11
申请号：US14235306
申请日：2012-07-29
IPC分类号： C07D249/08 , C07D403/12 , A61K31/4439 , A61K31/55 , A61K31/454 , A61K31/4196 , A61K31/506 , A61K31/498 , A61K31/497 , C07D401/12
CPC分类号： C07D249/08 , A61K31/4196 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D241/20 , C07D401/12 , C07D403/12 , C07D409/12
摘要： The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
摘要翻译： 本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及由结构式（I）表示的化合物或其药学上可接受的盐，其中变量的值和替代值如本文所定义和描述 。 本发明还包括结构式I化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗，调节和/或预防与CRM1活性相关的生理学条件。
-
公开(公告)号：US20150018332A1
公开(公告)日：2015-01-15
申请号：US14235342
申请日：2012-07-26
申请人： Vincent P. Sandanayaka , Sharon Shacham , Michael Kauffman , Sharon Shechter , Dilara McCauley , Yosef Landesman , William Senapedis , Jean-Richard Saint-Martin
发明人： Vincent P. Sandanayaka , Sharon Shacham , Michael Kauffman , Sharon Shechter , Dilara McCauley , Yosef Landesman , William Senapedis , Jean-Richard Saint-Martin
IPC分类号： C07D403/06 , C07D401/14 , C07D487/10 , C07D413/12 , C07D403/12 , C07D401/06 , C07D401/12
CPC分类号： C07D487/10 , C07D213/50 , C07D401/06 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12
摘要： The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
摘要翻译： 本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及由式（I）表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述。 本发明还包括结构式（I）化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗，调节和/或预防与CRM1活性相关的生理条件。
-
公开(公告)号：US09303000B2
公开(公告)日：2016-04-05
申请号：US13350864
申请日：2012-01-16
IPC分类号： C07D413/06 , C07D413/14 , A61K31/4439 , C07D401/06 , C07D249/08 , C07D403/06 , C07D417/06 , A61P9/10 , A61P35/00 , A61P31/12 , A61P29/00 , A61P19/02 , A61P17/00 , A61P17/06 , A61K31/4245 , A61K31/4196
CPC分类号： C07D249/08 , C07D401/06 , C07D403/06 , C07D413/06 , C07D413/14 , C07D417/06
摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
摘要翻译： 本发明一般涉及核转运调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑化合物，这些化合物及其药物组合物的合成和用途，例如在治疗，调节和/或 预防与CRM1活性相关的生理条件，例如治疗癌症和其它肿瘤性疾病，炎症性疾病，异常组织生长障碍和纤维化，包括心肌病，肺纤维化，肝纤维化，肾小球性肾炎和其他肾脏疾病，以及用于治疗病毒 感染（急性和慢性）。
-
公开(公告)号：US20120258986A1
公开(公告)日：2012-10-11
申请号：US13350864
申请日：2012-01-16
IPC分类号： C07D413/06 , C07D413/14 , A61K31/4439 , C07D401/06 , C07D249/08 , A61P9/10 , A61P35/00 , A61P31/12 , A61P29/00 , A61P19/02 , A61P17/00 , A61P17/06 , A61K31/4245 , A61K31/4196
CPC分类号： C07D249/08 , C07D401/06 , C07D403/06 , C07D413/06 , C07D413/14 , C07D417/06
摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
摘要翻译： 本发明一般涉及核转运调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑化合物，这些化合物及其药物组合物的合成和用途，例如在治疗，调节和/或 预防与CRM1活性相关的生理条件，例如治疗癌症和其它肿瘤性疾病，炎症性疾病，异常组织生长障碍和纤维化，包括心肌病，肺纤维化，肝纤维化，肾小球性肾炎和其他肾脏疾病，以及用于治疗病毒 感染（急性和慢性）。
-
公开(公告)号：US09428490B2
公开(公告)日：2016-08-30
申请号：US14235342
申请日：2012-07-26
申请人： Vincent P. Sandanayaka , Sharon Shacham , Michael Kauffman , Sharon Shechter , Dilara McCauley , Yosef Landesman , William Senapedis , Jean-Richard Saint-Martin
发明人： Vincent P. Sandanayaka , Sharon Shacham , Michael Kauffman , Sharon Shechter , Dilara McCauley , Yosef Landesman , William Senapedis , Jean-Richard Saint-Martin
IPC分类号： C07D403/06 , C07D403/12 , C07D401/14 , C07D405/14 , C07D401/08 , C07D401/12 , C07D403/14 , C07D413/12 , C07D487/10 , C07D401/06
CPC分类号： C07D487/10 , C07D213/50 , C07D401/06 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12
摘要： The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
摘要翻译： 本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及由式（I）表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述。 本发明还包括结构式（I）化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗，调节和/或预防与CRM1活性相关的生理条件。
-
公开(公告)号：US09079865B2
公开(公告)日：2015-07-14
申请号：US14235306
申请日：2012-07-29
IPC分类号： C07D249/08 , C07D403/12 , A61K31/4439 , A61K31/55 , A61K31/454 , A61K31/4196 , A61K31/506 , A61K31/498 , A61K31/497 , C07D401/12 , C07D241/20 , C07D409/12
CPC分类号： C07D249/08 , A61K31/4196 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D241/20 , C07D401/12 , C07D403/12 , C07D409/12
摘要： The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
摘要翻译： 本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及由结构式（I）表示的化合物或其药学上可接受的盐，其中变量的值和替代值如本文所定义和描述 。 本发明还包括结构式I化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗，调节和/或预防与CRM1活性相关的生理学条件。
-
公开(公告)号：US08513230B2
公开(公告)日：2013-08-20
申请号：US13041377
申请日：2011-03-05
IPC分类号： A61K31/4245 , A61P9/10 , C07D413/06 , C07D413/14
CPC分类号： C07D409/04 , A61K31/4196 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/505 , C07D207/337 , C07D231/12 , C07D233/64 , C07D249/08 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12
摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
摘要翻译： 本发明一般涉及核转运调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑化合物，这些化合物及其药物组合物的合成和用途，例如在治疗，调节和/或 预防与CRM1活性相关的生理条件，例如治疗癌症和其它肿瘤性疾病，炎症性疾病，异常组织生长障碍和纤维化，包括心肌病，肺纤维化，肝纤维化，肾小球性肾炎和其他肾脏疾病，以及用于治疗病毒 感染（急性和慢性）。
-
公开(公告)号：US20110275607A1
公开(公告)日：2011-11-10
申请号：US13041377
申请日：2011-03-05
IPC分类号： A61K31/4196 , C07D401/12 , A61K31/4439 , C07D403/12 , C07D417/04 , A61K31/427 , C07D401/14 , A61K31/444 , A61P35/00 , A61P29/00 , A61P11/00 , A61P1/16 , A61P13/12 , A61P31/12 , C07D249/08
CPC分类号： C07D409/04 , A61K31/4196 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/505 , C07D207/337 , C07D231/12 , C07D233/64 , C07D249/08 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12
摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
摘要翻译： 本发明一般涉及核转运调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑化合物，这些化合物及其药物组合物的合成和用途，例如在治疗，调节和/或 预防与CRM1活性相关的生理条件，例如治疗癌症和其它肿瘤性疾病，炎症性疾病，异常组织生长障碍和纤维化，包括心肌病，肺纤维化，肝纤维化，肾小球性肾炎和其他肾脏疾病，以及用于治疗病毒 感染（急性和慢性）。
-
9.发明授权Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors 失效含有异羟肟酸化合物的炔基作为基质金属蛋白酶/抑制剂公开(公告)号：US06753337B2
公开(公告)日：2004-06-22
申请号：US10029655
申请日：2001-12-21
申请人： Jeremy I. Levin , Aranapakam M. Venkatesan , James M. Chen , Arie Zask , Vincent P. Sandanayaka , Mila T. Du , Jannie L. Baker
发明人： Jeremy I. Levin , Aranapakam M. Venkatesan , James M. Chen , Arie Zask , Vincent P. Sandanayaka , Mila T. Du , Jannie L. Baker
IPC分类号： A61K31445
CPC分类号： C07D211/62 , A61K31/351 , A61K31/435 , A61K31/445 , A61K31/496 , C07D211/60 , C07D211/66 , C07D309/08
摘要： Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
摘要翻译： 下列化合物：可用于治疗关节炎，肿瘤转移，组织溃疡，创伤愈合异常，牙周病，骨病，糖尿病（胰岛素抵抗）和HIV感染。
-
公开(公告)号：US06489316B2
公开(公告)日：2002-12-03
申请号：US09771440
申请日：2001-01-26
IPC分类号： C07D49910
CPC分类号： C07D499/00 , A61K31/43 , A61K2300/00
摘要： The 6-(spirocyclopropyl)-penicillanic acid 4,4-dioxides of the general Formula (I): as defined herein above which exhibit beta-lactamase inhibiting activity, use of such compounds in combination with beta-lactam antibiotics for inhibiting beta-lactamases, pharmaceutical compositions and processes for preparing such compounds.
摘要翻译： 通式（I）的6-（螺环丙基） - 青霉烷酸4,4-二氧化物：如上文所定义，其显示β-内酰胺酶抑制活性，使用这些化合物与β-内酰胺抗生素联合用于抑制β-内酰胺酶 ，药物组合物和制备这些化合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.038 秒)
